Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced share reduction plans by several executives, indicating potential changes in insider sentiment and market dynamics [1][2]. Share Reduction Plans - Executive Jia Fei plans to reduce holdings by up to 12,200 shares, representing 0.0112% of the total share capital [1]. - Director Song Bofan intends to sell up to 2,300 shares, accounting for 0.0021% of the total share capital [1]. - Director Yan Hongbing aims to reduce holdings by up to 9,500 shares, which is 0.0088% of the total share capital [1]. - Senior executive Chen An plans to sell up to 11,200 shares, representing 0.0103% of the total share capital [2]. Financial Performance - Baicheng Pharmaceutical reported net profits of -52.74 million yuan for 2024 and 3.10 million yuan for the first half of 2025, with adjusted net profits of -72.63 million yuan and -1.17 million yuan respectively [2]. - The company went public on December 20, 2021, with an initial stock price of 79.60 yuan per share [2]. Stock Performance - The stock reached a peak price of 120 yuan on its first trading day but is currently in a state of decline [3]. - The total funds raised during the IPO amounted to 21.53 billion yuan, with a net amount of 18.63 billion yuan after expenses [3][4].
百诚医药4董事高管拟减持 扣非连亏2021年上市即巅峰